- Home
- LESL vs CUE Comparison
LESL vs CUE Comparison
Compare LESL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LESL
- CUE
- Stock Information
- Founded
- LESL 1963
- CUE 2014
- Country
- LESL United States
- CUE United States
- Employees
- LESL N/A
- CUE N/A
- Industry
- LESL Diversified Commercial Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- LESL Miscellaneous
- CUE Health Care
- Exchange
- LESL Nasdaq
- CUE Nasdaq
- Market Cap
- LESL 66.9M
- CUE 59.5M
- IPO Year
- LESL 2020
- CUE 2018
- Fundamental
- Price
- LESL $0.28
- CUE $0.72
- Analyst Decision
- LESL Hold
- CUE Strong Buy
- Analyst Count
- LESL 9
- CUE 2
- Target Price
- LESL $1.66
- CUE $3.00
- AVG Volume (30 Days)
- LESL 1.9M
- CUE 132.0K
- Earning Date
- LESL 08-06-2025
- CUE 11-13-2025
- Dividend Yield
- LESL N/A
- CUE N/A
- EPS Growth
- LESL N/A
- CUE N/A
- EPS
- LESL N/A
- CUE N/A
- Revenue
- LESL $1,250,568,000.00
- CUE $8,286,000.00
- Revenue This Year
- LESL N/A
- CUE N/A
- Revenue Next Year
- LESL $0.64
- CUE $13.27
- P/E Ratio
- LESL N/A
- CUE N/A
- Revenue Growth
- LESL N/A
- CUE N/A
- 52 Week Low
- LESL $0.27
- CUE $0.45
- 52 Week High
- LESL $3.63
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- LESL 34.91
- CUE 34.73
- Support Level
- LESL $0.27
- CUE $0.77
- Resistance Level
- LESL $0.34
- CUE $0.78
- Average True Range (ATR)
- LESL 0.02
- CUE 0.03
- MACD
- LESL -0.00
- CUE -0.01
- Stochastic Oscillator
- LESL 12.50
- CUE 9.53
About LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.